Deen BF, Shuler BK Jr, Sharon Fekrat S. Retinal venous occlusion associated with depot medroxyprogesterone acetate. Br J Ophthalmol 2007;91:1254.
238.
Kaunitz AM. Injectable long-acting contraceptives. Clin Obstet Gynecol 2001;44:73–91.
239.
Westhoff C. Depot medroxyprogesterone acetate contraception: metabolic parameters and mood changes. J Reprod Med 1996;41:401–406.
240.
Rodriguez MA, Kaunitz AM. An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women. Contraception 2009;80:4–6.
241.
La Vecchia C. Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical cancer. Contraception 1994;49:223– 229.
242.
World Health Organization. Depot medroxyprogesterone acetate (DMPA) and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:191–195.
243.
Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996;41(5 Suppl):419–427.
244.
Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396–403.
245.
Cullins VE. Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. J Reprod Med 1996;41(5 Suppl): 428–433.
246.
Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004;70:11–18.
247.
Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004;70:269–275.
248.
Guo-wei S. Pharmacodynamic effects of once a month combined injectable contraceptives. Contraception 1994;49:361–385.
249.
Kaunitz AM, Garceau RJ, Cromie MA, et al. Comparative safety, efficacy and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Contraception 1999;60(4):179– 187.
250.
Gao J, Wang SL, Wu SC, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel releasing IUD, and Norplant 2 implants in China. Contraception 1990;41:485–494.
251.